





# CENTRAL NERVOUS SYSTEM TUMORS(2)



Maram Abdaljaleel, MD  
Dermatopathologist & Neuropathologist



# Glioblastomas, IDH-wild-type, grade 4



- **Definition:**

Diffuse glioma that is IDH-wildtype and H3 wildtype and has **one or more** of the following histologic or genetic features:

- Microvascular proliferation
- Necrosis
- TERT promotor mutation
- EGFR gene amplification
- combined gain of entire chromosome 7 and loss of entire chromosome 10 [+7 / -10]

## **Glioblastomas, IDH-wild-type:**

- **The most common malignant glioma (50% of all primary malignant brain tumors in adults).**
- **Always grade 4** (no lower grade precursor)
- **Age:** 6th-8th decades of life
- **Site:** cerebral hemispheres (temporal , parietal, frontal lobes, basal ganglia and thalamus)

## **Clinically:**

- rapid progression
- Seizures, neurocognitive impairment, nausea, vomiting, and headache


**butterfly glioma:** Rapid infiltration of the corpus callosum with growth to the contralateral hemisphere leading to bilateral symmetrical lesion

## **Prognosis:**

- Very Poor (even with resection, chemotherapy and radiotherapy)
- the median survival is only about 15-18 months.

## Macroscopic:

- variation in the gross appearance of the tumor from region to region is characteristic (was called **glioblastoma multiforme**).
- Some areas are firm and white, others are soft and yellow (due to tissue necrosis), others show cystic degeneration and hemorrhage.



- **Microscopic:**

- Similar to astrocytoma, IDH- mutant, grade 4 with High cellularity, Prominent nuclear atypia, Brisk mitotic activity **and**

**Necrosis:** irregular zones of necrosis surrounded by dense accumulations of tumor cells (**palisading necrosis**)


**or**


**microvascular proliferation:**


the presence of abnormal vessels with walls composed **2  $\geq$**  layers of vascular wall cells.

**The presence of any of the following Molecular features (even in the absence of necrosis or microvascular proliferation) lead to the designation of glioblastoma, IDH wildtype, grade 4:**

- The presence of TERT promotor mutation
- EGFR gene amplification
- +7/-10 chromosome copy number changes







**OLIGODENDROGLIOMA, IDH- MUTANT, & 1P/19Q- CODELETED**

## **Definition:**

A **diffusely infiltrating**, slow-growing glioma with IDH1 or IDH2 mutation and codeletion of chromosomal arms 1p and 19q.

- 5-15% of gliomas
- **Age at diagnosis:** 40-50 yrs.
- **Location:** mostly in the cerebral hemispheres, mainly in the frontal or temporal lobes, white matter.


- The combination of surgery, chemotherapy, and radiotherapy yields an average survival of:
  - 10-20 years for WHO grade 2.
  - 5-10 years for WHO grade 3.
- **Grade 3 is more aggressive than grade 2 oligodendroglioma**
- **When corrected for tumor grade, oligodendrogliomas (CNS WHO grade 2,3) Have best prognosis among diffuse glial tumors**
- **NO grade 1 OR 4 oligodendroglioma**


## **Marcoscopic:**


- infiltrative tumors with blurring of grey matter-white matter boundary.
- +/- gelatinous gray mass, cysts, focal hemorrhage, and calcification.

## **Microscopic:**

- sheets of regular uniform cells resembling oligodendrocytes
- spherical nuclei containing finely granular chromatin (**salt and pepper**)
- The nuclei are surrounded by a clear halo of cytoplasm → **fried-egg appearance**.
- delicate network of “**chicken-wire**” –like anastomosing capillaries








- Calcification up to 90% of cases.
- Mitotic activity usually is absent or low (Ki67<5%)
- No spontaneous necrosis
- No microvascular proliferation

**oligodendroglioma , IDH- mutant, & 1p/19q- codeleted, WHO grade 3**



## oligodendroglioma , IDH- mutant, & 1p/19q- codeleted WHO grade 3:

- Defined as: An IDH-mutant and 1p/19q-codeleted oligodendroglioma with focal or diffuse histological features of anaplasia (in particular, **pathological microvascular proliferation and/or brisk mitotic activity with or without necrosis**).

# IDHm 1p/19q-codeleted Oligodendrogliomas, grades 2-3

Essential diagnostic criteria for oligodendroglioma, IDH-mutant and 1p/19q-codeleted, WHO grade 2

A diffuse glioma

**WITH**

an IDH1 codon 132 or IDH2 codon 172 missense mutation\*

**AND**

combined whole arm deletions of 1p and 19q

**AND**

absence of histological features of anaplasia.

Essential diagnostic criteria for oligodendroglioma, IDH-mutant and 1p/19q-codeleted, WHO grade 3

A diffuse glioma

**WITH**

an IDH1 codon 132 or IDH2 codon 172 missense mutation\*

**AND**






combined whole arm deletions of 1p and 19q

**AND**



histological features of anaplasia, including brisk mitotic activity and/or pathological microvascular proliferation with or without necrosis

**AND/OR**

homozygous *CDKN2A* deletion\*\*



UPDATE



**Ependymoma, WHO 2&3**

# Ependymoma:

- **Definition:**

glioma, Mostly arise next to the ependyma-lined ventricular system, including the central canal of the spinal cord.

- **Location:**

- **posterior fossa:** near the 4<sup>th</sup> ventricle, accounting for 5-10% of tumors in the first two decades of life
- **supratentorial**
- **Spinal:** the most common location in adults and in patients with NF2

- **Age:**
  - In the first 2 decades of life; near **the 4<sup>th</sup> ventricle (post. Fossa)** accounting for 5-10% of primary brain tumors in this age group.
  - In adults the **spinal cord and supratentorial ependymomas occur with almost equal frequency**
- The clinical outcome for completely resected supratentorial and spinal ependymomas is better than for those in the posterior fossa.

## Ependymoma, WHO grade 2, microscopic:

- uniform small cells with round to oval nuclei and granular chromatin in a fibrillary background
- low cellularity
- low mitotic count
- No necrosis or MVP
- Cilia and microvilli are seen on ultrastructural examination.

## Ependymoma WHO grade 2, Morphology:

- Tumor cells may form glandlike structures (rosettes) → **Rosette formation:**

- **Ependymal rosettes:** diagnostic hallmark of ependymoma (25%)
- **perivascular pseudorosettes:** not specific for ependymoma (seen in glioblastoma and medulloblastoma)




## Ependymal rosettes:


- tumor cells arranged around central canal or lumen that resemble the embryologic ependymal canal, with long, delicate processes extending into a lumen.

## Perivascular pseudorosettes:


- tumor cells radially arranged around vessels.
- Called “pseudo” because the central structure is not formed by the tumor itself, but instead represents a native, non-neoplastic element.

# Ependymal rosettes





**perivascular pseudorosettes**



# Ependymomas

		Age	Sex	WHO grade	Molecular Features	Outcome
Supratentorial	ST-SE		♂♂♂♀	1	Balanced genome	
	ST-ZFTA		♂♂♀		<del>ZFTA</del> fusions Chromothripsis CDKN2A/B loss	
	ST-YAP1		♂♀♀♀		YAP1 fusions	
Infratentorial	PF-SE		♂♂♂♀	1	Balanced genome	
	PFA		♂♂♀		EZH2 mutations H3K27M mutations Chr. 1q gain	
	PFB		♂♀		Chromosomal instability	
Spinal	SP-SE		♂♀	1	Chr. 6q deletion	
	SP-EP		♂♂♀	2 / 3	NF2 mutations	
	SP-MP		♂♀	2	Chromosomal instability	
	SP-MYCN		♂♀		MYCN amplification (Chr. 2p)	

UPDATE

- **Anaplastic ependymomas, WHO grade 3:**
- Show less evident ependymal differentiation.
- brisk mitotic rates, and microvascular proliferation carry more prognostic impact than necrosis and atypia.

